Pulmonology

The analysis of 2021 data show lung cancer screening rates increased 8.4% since 2019 to 21.2%.

Investigators explain understanding these disparities is crucial for developing targeted interventions to improve screening rates and reduce health inequities.

"Our research is unique in its attempt to describe a high-need, high-cost patient population who might benefit from increased monitoring or intervention," Dr. Ann Cameron says.

Criner and colleagues concluded that the 5-year results from the EMPROVE trial demonstrated that Spiration Valve System (SVS) treatment was safe and durable, effectively improving lung function in patients with emphysema

Diagnosis, evaluation, and treatment recommendations for pregnant individuals with asthma follow similar principles as for nonpregnant patients, but investigators address specific challenges.

“We all know that exacerbations are the most costly disease impact of COPD,” study investigator Dr. Charlie Strange says.

The team aimed to examine the impact surgical treatment of obstructive sleep apnea had on periodic limb movement index in pediatric patients.

Dr. Jean-Pierre Llanos Ackert and Dr. Chris Ambrose discuss the latest data on the breakthrough biologic for severe asthma.

Patients treated with NAL ER demonstrated a 75.1% decrease in daytime cough frequency and a 76.1% decrease in 24-hour cough frequency compared with placebo.

Investigators Dr. Jean-Pierre Llanos Ackert and Dr. Chris Ambrose share insight on the efficacy of tezepelumab in severe, uncontrolled asthma, and baseline predictors of enhanced response which support tezepelumab as a promising biologic treatment option.

Late-breaking data validates the FDA clearance of Cytovale's IntelliSep test, demonstrating its potential to aid in the early detection of sepsis in US emergency departments, with the aim of improving patient outcomes.

Late-breaking data from ATS 2023 show new positive evidence of the innovative in-vitro diagnostic tool IntelliSep test that measures the viscoelastic properties of leukocytes, showing promising results for rapid sepsis diagnosis in EDs.

A post hoc analysis shows benralizumab was even more efficacious in patients with concomitant nasal polyps at both 6 and 12 months.

An analysis of the phase 3 NAVIGATOR trial shows tezepelumab did not provide differing efficacy among men and women, despite historic trends of disparate severe asthma outcomes among sexes.

Dr. Rutland emphasizes the importance of understanding cellular communication and its potential to manipulate disease processes for patient benefit, including the observed link between ILD, inflammation, scarring, and pulmonary hypertension.

Promising results from the ATS Conference suggest that AD109, an oral treatment for obstructive sleep apnea, demonstrated significant reduction of AHI and potential mitigation of daytime fatigue.

Dupilumab demonstrates significant improvements in patients with COPD, type 2 inflammation by reducing exacerbations, improving lung function and quality of life, and alleviating respiratory symptoms.

An analysis of the COPDGene Study presented at ATS 2023 suggests presence of mucus plugs in medium- to large-sized airways were associated with an increased risk of mortality in adjusted models.

AD109 shows the potential to address an unmet need in obstructive sleep apnea treatment.

As a result of these practices, asthma disparities have been amplified due to the concentration of poverty, heightened exposure to environmental hazards, and inadequate housing quality in these communities.

The increased use of tobacco-free nicotine products highlights the need for physicians to stay informed about nicotine pouches and be prepared for discussions with their patients.

Relocation led to a reduction in asthma exacerbations, exceeding the effect of inhaled corticosteroids, and was similar to biologic agents.

The phase 3 clinical trials evaluating ziritaxestat for treating idiopathic pulmonary fibrosis showed no improvement in clinical outcomes leading to the termination of the trials due to lack of efficacy.

At West Penn Hospital, the harmonica program, currently in the pilot phase, aims to demonstrate its benefits in improving respiratory symptoms, reducing exacerbations, and enhancing patients' quality of life.

"Playing the harmonica has a therapeutic effect because of the pursed lip breathing technique it requires," Dr. Becky Jordan says in an interview.

Results from the NIH RECOVER Initiative study show an 89% risk of long COVID in women with sleep apnea and 59% in men when compared with adults without the condition.

The long-term extension SENSCIS-ON trial shows patients receiving nintedanib over 3 years were not at significantly greater risk of serious adverse events or outcomes.

Results showed standardized reporting was frequently used in low-dose computed tomography lung screening, with the majority of instances being considered reportable to the clinician and requiring follow-up.

Data show older age, being female, having a high BMI, smoking, comorbidities, and previous hospitalization or ICU admission with COVID-19 were associated with an increased risk of developing Post-COVID-19 condition.

Data indicate higher BMI is associated with an increased risk of severe respiratory disease, including COVID-19, with the highest risk observed in those with a BMI in the range of 35-60.